Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Data
Biotech
J&J lymphoma CAR-T hits 100% ORR in 10 patients
Of the 10 patients who had received one line of prior treatment, an objective response rate of 100% was recorded.
Darren Incorvaia
Jun 13, 2025 1:22pm
Merck KGaA sheds light on failed portion of phase 2 lupus trial
Jun 12, 2025 9:41am
Merck's oral PCSK9 inhibitor leader reduces cholesterol in ph. 3
Jun 9, 2025 9:00am
NewAmsterdam links lipid drug to drop in Alzheimer's biomarker
Jun 9, 2025 8:25am
Metsera posts amylin data, eyes monthly GLP-1 combo
Jun 9, 2025 7:00am
Otsuka's kidney disease drug halves UPCR levels in ph. 3 study
Jun 6, 2025 6:26am
